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Introduction: Type 2 diabetes (T2DM) is a major health concern with significant personal
and healthcare system costs. There is growing interest in using shared medical
appointments (SMAs) for management of T2DM. We hypothesize that adding
mindfulness to SMAs may be beneficial. This study aimed to assess the feasibility and
acceptability of SMAs with mindfulness for T2DM within primary care in Australia.
Materials and Methods: We conducted a single-blind randomized controlled feasibility
study of SMAs within primary care for people with T2DM living in Western Sydney,
Australia. People with T2DM, age 21 years and over, with HbA1c > 6.5% or fasting
glucose >7.00 mmol/L within the past 3 months were eligible to enroll. The intervention
group attended six 2-h programmed SMAs (pSMAs) which were held fortnightly. pSMAs
included a structured education program and mindfulness component. The control group
received usual care from their healthcare providers. We collected quantitative and
qualitative data on acceptability as well as glycemic control (glycated hemoglobin and
continuous glucose monitoring), lipids, anthropometric measures, blood pressure, self-
reported psychological outcomes, quality of life, diet, and physical activity using an
ActiGraph accelerometer.
Results: Over a 2-month period, we enrolled 18 participants (10 females, 8 males) with a
mean age of 58 years (standard deviation 9.8). We had 94.4% retention. All participants in
the intervention group completed at least four pSMAs. Participants reported that
attending pSMAs had been a positive experience that allowed them to accept their
diagnosis and empowered them to make changes, which led to beneficial effects
including weight loss and better glycemic control. Four pSMA participants found the
mindfulness component helpful while two did not. All of the seven participants who
contributed to qualitative evaluation reported improved psychosocial wellbeing and found
the group setting beneficial. There was a significant difference in total cholesterol levels atn.org October 2020 | Volume 11 | Article 5707771
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Frontiers in Endocrinology | www.frontiersi12 weeks between groups (3.86 mmol/L in intervention group vs. 4.15 mmol/L in the
control group; p = 0.025) as well as pain intensity levels as measured by the PROMIS-29
(2.11 vs. 2.38; p = 0.034).
Conclusion: pSMAs are feasible and acceptable to people with T2DM and may result in
clinical improvement. A follow-up fully-powered randomized controlled trial is warranted.
Clinical Trial Registration: Australia and New Zealand Clinical Trial Registry, identifier
ACTRN12619000892112.Keywords: type 2 diabetes, primary care, shared medical appointments, mindfulness, glycemic control, feasibility
study, pSMAs for type 2 diabetesINTRODUCTION
Diabetes is a major cause of morbidity and mortality globally. An
estimated 8.5% of the world’s population lives with diabetes, and
diabetes was the direct cause of 1.6 million deaths, or 11% of all
deaths, in 2014 worldwide (1). In 2019, global health expenditure
on diabetes was estimated at USD$760 billion (2). In Australia,
type 2 diabetes (T2DM) is diagnosed once every 5 min (3) and
the number of diagnoses is expected to double by 2033 to 3.5
million (4). T2DM is a National Health Priority Area (5) with an
annual financial cost of AUD $14.6 billion (3). Health
consequences of T2DM are devastating and include stroke and
coronary heart disease, blindness, renal failure, neuropathy, and
peripheral vascular disease (4). Moreover, T2DM is one of the
leading causes of morbidity and mortality in Australia and
commonly causes psychological distress (4). It is estimated that
every 1% reduction in HbA1c significantly reduces risk of T2DM
related deaths (−21%) and microvascular complications
(−37%) (6).
There is growing interest in the possible role of shared
medical appointments (SMAs) in managing chronic disease
(7). SMAs are defined as “consecutive individual medical visits
carried out in a supportive group setting of similar patients where
all can listen, interact, and learn” and may have the advantages of
being cost-effective, encouraging peer support, improving
clinician satisfaction, and reducing repetition of health
information (8). SMAs involve a medical practitioner [e.g.
general practitioner (GP) or specialist] consulting with patients
sequentially among a group of patients who can interact
throughout the consultation under the guidance and direction
of a trained facilitator (usually a practice nurse or other allied
health professional). A variant of SMAs is the programmed SMA
or pSMA, which incorporates a structured educational
component. SMAs are also a time-efficient way of providing
chronic disease management, and are becoming increasingly
popular within primary care (9).
The evidence on SMAs for T2DM is inconsistent, mostly due
to heterogeneity of the interventions and sample characteristics;
however, there is some evidence for reduction of HbA1c, weight,
blood pressure, lipids, and improved quality of life and patient
satisfaction (10). SMAs are also cost-effective compared to one-
on-one care (8). There is a compelling need to further explore the
role of SMAs in the management of diabetes and itsn.org 2complications as well as resulting psychological distress within
primary care. Of note, there are no published randomized
controlled trials evaluating the effectiveness of SMAs for
T2DM in Australia.
Mindfulness-based interventions may be beneficial for quality
of life, anxiety, and depression in people with T2DM but the
evidence for physiological outcome changes is inconsistent (11).
However, mindfulness meditation may play an important
adjunctive role in managing other metabolic conditions. For
example, there is evidence from systematic reviews that
mindfulness meditation in the general population can improve
eating behaviors and increase physical activity (11–16) by
teaching participants to become more accepting of the physical
discomfort of portion control and physical exercise and is
effective for weight loss.
SMAs may therefore represent an innovative model of care that
could improve glycemic control in people with T2DM and enhance
T2DM management within primary care; however, more robust
evidence is required. Prior to undertaking expensive randomized
controlled trials, feasibility studies are recommended in order to
assess the likelihood of successful recruitment of a fully-powered
trial as well as the acceptability of trial procedures to participants. To
this end, we conducted a mixed-methods study evaluating the
feasibility and acceptability of pSMAs for people with T2DM. We
hypothesized that including a mindfulness component to pSMAs
would improve adherence to lifestyle recommendations and
facilitate healthier behaviors.MATERIALS AND METHODS
The primary objective for the study was to assess recruitment,
retention, and adherence rates as well as acceptability of trial
procedures. Secondary objectives were to determine an effect size
for pSMAs vs. usual care and examine for a trend between groups
for change in glycemic control, blood pressure, lipids,
anthropometric measures, quality of life, psychological outcomes,
and lifestyle habits.
Study Design
This was a mixed-methods study that included a prospective
parallel pragmatic single-blind randomized controlled feasibilityOctober 2020 | Volume 11 | Article 570777
Ee et al. Shared Medical Appointments and Diabetestrial. Feasibility was also assessed using qualitative methods (a
focus group and semi-structured interviews).
Ethics approval was granted by the Western Sydney
University Human Research Ethics Committee (H12925 16/11/
2018). The trial was registered on the Australian New Zealand
Clinical Trials Registry (ACTRN12619000892112).
Randomization and Blinding
Participants were randomized in a 1:1 ratio to receive either the
intervention (pSMA) or usual care. The randomization sequence
was created using a computer program (www.sealedenvelope.
com) by a researcher external to the research team. Permuted
blocks of six were used. Allocation was concealed using
consecutively number sealed opaque envelope. Before opening
each envelope, the research assistant wrote the participant’s
name on the envelope, the date, and signed the envelope as a
record of randomization. Investigators (apart from the research
assistant who implemented the randomization process) were
blinded to treatment allocation but participants were not. The
research assistant who collected anthropometric measurement
collection (JH) was also blinded to allocation.
Sample Size
As this was a feasibility study, a sample size calculation was not
required. SMAs typically involve 10–12 participants per group.
We aimed to randomize 24 participants altogether (12 to a
pSMA group, 12 to usual care).
Participants
The study took place in an academic primary care clinic setting
(Western Sydney Integrative Health—an academic clinic within
Western Sydney University) in Sydney.
Recruitment began on 12th March 2019 and ended on 15th
May 2019. The study was advertised on Diabetes NSW & ACT
social media pages on 15th March and in the Diabetes NSW &
ACT newsletter in 4 April. The study was advertised on
Facebook from 19th March for six days and on Google from
23rd March for 7 days. Other promotion channels were the
Western Sydney University online staff newsletter on 12th March
and 16th April 2019, and the India Club newsletter 4th April 2019
(a voluntary organization established to promote the interests of
the Indian Australian community).
Participants were eligible if they were aged over 21 years, lived
in the Greater Western Sydney region in Australia, had a
diagnosis of T2DM, and had evidence of HbA1c > 6.5% or
fasting blood glucose > 7.00 mmol/L within the preceding 3
months. Exclusion criteria were:
• Unable to attend for pSMAs;
• Pregnant or planning pregnancy in the next 3 months;
• Serious medical or psychological conditions (e.g., metastatic
cancer and poorly controlled schizophrenia);
• Not fluent in English (unable to follow conversations and
instructions in English and unable to read English); and
• Known allergy to medical adhesives (because of the risk of allergy
to adhesive from the continuous glucose monitoring system)Frontiers in Endocrinology | www.frontiersin.org 3Outcomes
Primary outcome measures were recruitment rate, retention rate,
and adherence rate. Acceptability was also assessed by an exit
questionnaire and qualitative methods.
We used the following to define our feasibility measures:
• Recruitment rates: number of enquiries and number of
enrolments per month of active recruitment; percentage
conversion to enrolment measured as n enrolled/n of
enquiries, and n enrolled/n potentially eligible.
• Retention rate: n completing 12-week intervention and
outcome measures/n enrolled.
• Adherence rate: n completing at least 4 of 6 PSMAs/total n
allocated to the intervention group.
Secondary outcome measures were:
• Glycemic management (from HbA1c, and also time in range/
mean glucose measured by a 14-day FreeStyle Libre
Continuous Glucose Monitor);
• Fasting lipids;
• Anthropometric measures (weight, body mass index/BMI,
waist and hip circumference, and waist/hip circumference
ratio);
• Blood pressure;
• Anxiety and depression using the Beck Depression Inventory
(BDI) (17) and State Anxiety Index (SAI) (18);
• Diabetes-related distress using the Problem Areas in Diabetes
(PAID) scale (19);
• Generic quality of life and wellbeing using the EuroQol-5D
(EQ5D) (20) and Patient-Reported Outcomes Information
System questionnaire (PROMIS-29) (21);
• Self-reported diet quality using three questions about fruit,
vegetable and takeaway intake taken from the NSW
Population Health Survey Questionnaire 2017, which is an
annual telephone-based survey of 15,000 adults in the state of
New South Wales, Australia (22);
• Physical activity levels as measured by an ActiGraph
accelerometer (minutes per week of light, moderate and
vigorous activity; number of steps per day; number of
sedentary hours per day); and
• Number of minutes of mindfulness practice per week
(measured using a home meditation log)Pre-Intervention and Baseline Visit Data Collection
At a pre-intervention visit, a research assistant obtained written
informed consent and details on concomitant medications and past
medical history. Weight was measured to the nearest 0.1 kg using a
calibrated medical-grade digital scale (Seca 803) and waist and hip
circumference to the nearest 0.1cm using a medical-grade steel tape
measure (Seca 201). Height was measured using a wall-mounted
stadiometer. Anthropometric measures and blood pressure were
measured according to standard procedures (23). Participants
completed a demographic and medical questionnaire that
collected information about age, ethnicity, education, cigarette use,
year of diagnosis of T2DM, and presence of complications ofOctober 2020 | Volume 11 | Article 570777
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electronic data capture tools hosted at Western Sydney University
(24, 25). REDCap (Research Electronic Data Capture) is a secure,
web-based software platform designed to support data capture for
research studies, providing: 1) an intuitive interface for validated
data capture; 2) audit trails for tracking data manipulation and
export procedures; 3) automated export procedures for seamless
data downloads to common statistical packages; and 4) procedures
for data integration and interoperability with external sources.
A 14-day FreeStyle Libre Continuous Glucose Monitor sensor
was inserted into the posterior upper arm. We asked participants
to wear an ActiGraph accelerometer (GT3X, LLC, Fort Walton
Beach, FL) on their right hip for 5–7 days to measure light,
moderate, and vigorous physical activity, as well as their number
of steps per day and time spent in sedentary behavior. A
sufficient number of days are needed for the resulting average
MVPA per day to reflect the participants usual PA
level. However, it is equally important to not overburden
participants. Evidence across multiple accelerometer studies
shows that at least 3 days of PA data are needed to reliably
estimate usual or habitual PA levels (26). As accelerometer
compliance is sometimes low, asking participants to wear the
device for 5–7 consecutive days is likely to ensure at least three
valid days of PA data, without overburdening participants more
than necessary. We removed non-wear-time from the
participants’ data files by identifying strings of consecutive zero
count-values lasting ≥60 min, while allowing for a 1- to 2-min
spike tolerance of counts between 0 and 100. After removing
wear-time, a calendar day was considered valid if the
accelerometer was worn for ≥10 h, and participants with at
least 3 valid days were included in the analysis. Using established
cut-points we calculated participants’ sedentary, light, moderate,
and vigorous physical activity (27).
Participants attended for blood collection at private pathology
centres (Laverty Pathology) after an overnight fast, a few days prior
to the baseline visit. Whole blood was analyzed for glycated
haemoglobin using ion-exchange high-performance liquid
chromatography/HPLC (D-100™ HbA1c test; Bio-Rad
Laboratories). Serum was analyzed for total cholesterol using the
enzymatic method (ADVIA® Chemistry Concentrated Cholesterol
Reagent/CHOL_c; ADVIA® Chemistry Systems) and for
triglycerides using the Fossati three-step enzymatic reaction with a
Trinder endpoint (ADVIA® Chemistry Triglycerides_2
Concentrated/TIRG_c assay; ADVIA® Chemistry Systems).
At the baseline visit, the Freestyle Libre sensor was removed
and disposed of, and data was downloaded from the sensor. The
accelerometer was collected from the participant, and any
adverse events that had been experienced were recorded.
End of Treatment Data Collection
Participants attended a Week 12 clinic visit during which adverse
events that were reported were recorded and concomitant
medications and medical history were updated. Anthropometric
measures, blood pressure, and PROMswere collected as per the pre-
intervention visit. Participants also completed an exit survey about
acceptability of trial procedures; however, due to an administrative
error only the first question was completed at Week 12, with theFrontiers in Endocrinology | www.frontiersin.org 4remainder of the questions completed in December 2019 when the
research team discovered the missing data. Participants were fitted
with another 14-day FreeStyle Libre Continuous Glucose Monitor
sensor and wore that for 14 days, then returned for removal of the
sensor. Participants were provided with an accelerometer to wear
for 5–7 days and had further testing for HbA1c and
fasting lipids.246.
Intervention: Programmed Shared Medical
Appointments With Mindfulness
The intervention was a series of face-to-face pSMAs with an
adjunctive mindfulness meditation component. The frequency,
length and duration of pSMAs is based on a study by Egger et al.
on weight loss for people with obesity (9) as well as from
reviewing the literature. The frequency of SMAs for people with
T2DM in other studies has varied from every 3 weeks to every 3
months, with more frequent SMAs being generally associated
with improved outcomes for weight loss. The feedback from study
by Egger et al. was that monthly SMAs were too infrequent for
weight loss, and fortnightly SMAs were feasible. Most SMAs are
between 6-12 people of an optimum of six sessions based on the
earlier GutBuster’s Program by Egger (28).
The 12-week program included six fortnightly 2-h pSMAs
delivered by a GP, facilitator (accredited diabetes educator),
documenter, and a meditation teacher. The pSMA ran as follows:
• A confidentiality agreement was signed by all participants at
the beginning of the first SMA;
• Each participant was asked for their questions for the GP, and
these were written down on a whiteboard;
• 60 min of SMAs where the GP consulted with each
participant consecutively for approximately 5–7 min at a
time per individual consultation;
• 30 min of structured education delivered by the facilitator/
diabetes educator. These were made interactive through the
use of props and handouts, for example, food models, nail
files, and fact sheets from the National Diabetes Services
Scheme, an initiative of Diabetes Australia (Australia’s
national body for people affected by diabetes); and
• 20 min of guided mindfulness meditation delivered by a
meditation teacher (see Appendix 2 for more information).
For quality assurance, and to ensure fidelity of the
intervention, a researcher (CE) observed one of the pSMAs
and provided corrective feedback as appropriate.
Eight topics on diabetes education were offered to the
participants who were then able to choose the six topics that
they wished to have delivered (see Appendix 1 for details on the
education program). Participants were encouraged to set their
own lifestyle goals based on the RACGP handbook on general
practice management of T2DM (29). Key goals included weight
loss of 5%.
The mindfulness component was delivered by an experienced
meditation teacher and consisted of 15–20 min of guided
mindfulness meditation. Mindfulness was defined as “paying
attention in a particular way; on purpose, in the present moment,
and nonjudgementally” (30). Each guided mindfulness sessionOctober 2020 | Volume 11 | Article 570777
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were encouraged to practice mindfulness meditation at home
and to record it in meditation logs. More details are available in
Appendix 1.
Control
Participants allocated to the control group received usual care
only, defined as care as provided by their usual GP. They were
encouraged to register for the GetHealthy NSW program (31),
which is a free telephone-based lifestyle coaching service, and to
use the free Smiling Mind (32) mindfulness meditation
app regularly.
Prior and Concomitant Medications
There were no restrictions on concomitant medications in this
trial. Concomitant medications were monitored using a
Concomitant Medication Log.
Participant Reimbursement
All participants were reimbursed AUD$50 in total after
attending the 12-week visit, for travel costs associated with
the study.
Qualitative Interviews
We conducted a qualitative evaluation of the acceptability and
feasibility of the pSMA program. Participants who received the
pSMAs intervention were invited to provide feedback on the
acceptability of the intervention in a 90 to 120-min focus group
or a one-on-one, semi-structured interview.
The focus group and interviews were conducted by
researchers external to the main study (SD and KM) so as to
not influence participant responses in any way. Key questions in
the interview schedule included feedback on the content,
structure and frequency of the pSMAs, perceived value of the
mindfulness component, and suggestions for improvement.
Focus groups and interviews were audio-recorded and
transcribed verbatim by a professional transcribing service.
Statistical Methods and Data Analysis
Recruitment, retention, and adherence rates are presented with
descriptive statistics. We used ANOVA to identify between-group
differences, adjusting for baseline score as a co-variate. Where data
was not normally distributed, we used non-parametric measures
(Mann-Whitney U tests). Intention-to-treat analysis was used.
Analysis and interpretation of the findings was conducted by
blinded investigators. Investigators agreed on the interpretation of
the findings before revealing the allocation of either group. At the
time of interpretation offindings, the two groups were only referred
to as “Group 1” or “Group 2”. Group numbers were also not
revealed as this could have compromised blinding.
The de-identified transcripts were analyzed using thematic
analysis. Thematic analysis encompasses identifying and
analyzing reoccurring patterns of significance in regard to the
research question being addressed (33). Themes and sub-themes
meaningful to the research matter emerged as a result of these
reoccurring patterns within the data. Transcripts were codedFrontiers in Endocrinology | www.frontiersin.org 5using Quirkos v.1.5.1 software (34). Participant excerpts are
included in the results labelled by a participant identification
number to highlight key themes and sub-themes.RESULTS
Recruitment
Facebook advertisement received 11,576 total impressions with an
engagement rate of 12% and CPR of $0.69c, at a total cost of AUD
$100 over six days. The Google advertisements generated 144
clicks and 4,320 impressions at a cost of AUD$380 over 7 days.
Figure 1 describes participant flow through the trial.
Baseline Data
Tables 1, 2 describe demographic and medical characteristics,
and between-group comparison of outcomes at baseline. There
were no statistically significant between-group differences for
demographic characteristics or outcomes measures at baseline.
Primary Outcomes
Recruitment, Retention, and Adherence
Our recruitment resulted in an average of 26 enquiries and nine
enrolments per month of active recruitment. The conversion rate
from enquiry to enrolment was 37.5% (18/48) and from eligible
to enrolled was 85.7% (18/21). From those that were excluded,
40% (12/30) did not meet the study’s inclusion criteria, 33.3%
(10/30) were lost to follow up, 13.3% (4/30) declined to
participate (no reason provided), 10% (3/30) were eligible for
the study but were unable to attend the baseline visit and one
participant declined to participate over safety concerns (see
Figure 1). Of the 18 participants enrolled, 17 completed the
12-week intervention and outcome measures (94.4% retention).
All of the participants in the intervention group completed at
least 4 of 6 PSMAs.
Acceptability: Exit Questionnaire Data
Based on exit questionnaire data, most of the participants in the
pSMA group found the education sessions helpful (8/9), enjoyed
being able to talk to other people with diabetes (7/9),
contributing to research (7/9), found the mindfulness sessions
helpful (6/9), and enjoyed the extra attention toward their health
and wellbeing (5/9) (Table 1). However, few participants
reported finding the mindfulness home practice or workbooks
helpful (2/9), or reported losing weight (2/9).
Some quotes around this question included: “it was a great
experience attending group sessions” (ID3); “being in the control
group I did not get much out of the study, except the opportunity
to wear a sensor” (ID1); “Nothing to me was detrimental. The
experience helped me to better understand my diabetes through
the course contents and interaction with the other participants”
(ID6). Participants reported for example “It was great being able
to share with others, and hearing others talk about their health
and see the same things we go through” (ID10), “This is my first
experience in SMA. I liked it and feel better than a one-on-one GP
appointments” (ID16).October 2020 | Volume 11 | Article 570777
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the trial, six from the pSMA group and four from the control
group reported there was “nothing” that they did not enjoy. One
participant said the SMAs were too far away from where he/she
lived/worked, one did not enjoy the mindfulness practice, and
one reported a technical error with a CGMS sensor. In the
control group, one participant noted that the exit survey should
have been tailored to the allocation groups (i.e., not asking
control group participants the questions about PSMAs), and
one noted that they could not access continuous glucose
monitoring results in real time using a mobile application as
advised, because the sensors that were used were not compatible
with the Australian mobile application. Three participants from
the control group reported that the “did not learn anything new”.
Shared Medical Appointments
There were six responses from the question about feedback on
the SMA’s overall. All of the six responses were positive
comments, e.g., “very good” (ID16), and “excellent and should
do more for these sessions” (ID3).
The most important features of PSMAs according to
participants were:Frontiers in Endocrinology | www.frontiersin.org 6• The ability to share experiences and tips in a group discussion
(6/9), including “a better idea of the effect diabetes has on people
[and] how they managed their diabetes and lived their lives” (ID6);
• Expanded knowledge of diabetes from health professionals
(5/9), which included education on results of tests, side effects
of medications, a better understanding of diabetes overall, and
increased confidence and awareness about diabetes;
• Sense of not being alone in experience of diabetes (5/9),
including realizing that other people with diabetes were also
struggling with their weight; and
• The style and approach of the facilitator and GP (friendly and
non-judgmental, “knowledgeable” (ID 18), “just made it easier
to talk about things” (ID 10), “relaxed environment” (ID 6)
where participants felt free to ask questions) (5/9).
Table 3 describes the additional feedback on pSMAs.
Representative quotes include: “Timing, duration and frequency
was just right for me” (ID16); “was able to understanding how other
where struggling/controlling their diabetes” (ID3); “being able to
share and relate to others was very helpful” (ID10); “GP was
knowledgeable and explained side effects of medications. In my
experience doctors haven’t done this” (ID18).FIGURE 1 | CONSORT flowchart of participant flow.October 2020 | Volume 11 | Article 570777
Ee et al. Shared Medical Appointments and DiabetesFacilitator and GP. We received eight responses for feedback on
the facilitator and seven for the GP. All were positive with the
facilitator rated from “fantastic” (ID16), to “good” (ID6). Par-
ticipants described the facilitator as “really good and knowl-
edgeable” (ID3), “made us all feel relaxed” (ID10), “thoughtful”
(ID4). The characteristics of being friendly, approachable, and
knowledgeable, were highly valued by the participants. Similarly,
the GP was rated from “good” to “the best person” (ID3). ID4
noted “Wow what a gentle caring GP”.
Mindfulness. Six participants provided feedback on the mindful-
ness sessions. Four of these participants had positive feedback
including “exceptionally good” (ID16) and “very helpful and relax-
ing” (ID10). ID4 wrote “In walked this quite softly spoken woman
and I thought what is this. Within 15 mins I was hooked. Relaxing
and insightful”. Two participants did not find the sessions useful.
Six participants from the pSMA group provided feedback on
home mindfulness practice. Feedback was mixed. One
participant noted that more assistance was needed (ID16).
Another noted that, while mindfulness could be helpful, it was
“very difficult for busy people” (ID10). Two participants found
home practice helpful while another did not find it helpful.
Trial Procedures. Table 4 describes the results on acceptability of
trial procedures.Frontiers in Endocrinology | www.frontiersin.org 7Qualitative Evaluation of Trial Feasibility and
Acceptability
Seven out of the nine participants from the pSMA group
contributed to the qualitative assessment of trial feasibility and
acceptability (five males and two females). One focus group was
held on the 2nd of October 2019, attended by five participants,
and two interviews were conducted over the telephone.
Four central themes meaningful to the study were identified
from the data: (1) perceptions and attitudes toward pSMAs, (2)
perceived effects of the pSMAs, (3) support and materials, and











- Male 6 2
- Female 3 7
Ethnicity 0.842*
- European 3 3
- Oceanic 3 2
- Asian 3 4
Mean years diagnosed with T2DM
(SD)
16.67 (5.97) 14.11 (10.54) 0.536†
Smoking status 1.000‡
- Ex-smoker 2 2
- Never smoked 7 7
Complications of T2DM
- Ischemic heart disease 1 2
- Stroke 0 0
- Peripheral vascular disease 0 0
- Foot ulcers 0 1
- Retinopathy 0 1






- Hypercholesterolemia 3 5
- Hypertension 5 4
- Hypothyroidism 2 2
- Depression 0 2
On insulin therapy 4 2 0.620‡†T2 test; ‡Fisher’s exact test; Mann-Whitney U test *Pearson Chi square; SD,







Glycemic control and lipids
Hb1Ac-NGSP (%) 7.92 (1.09) 7.30 (0.44) 0.117‡
Hb1Ac-IFCC (mmol/mol) 62.89 (11.90) 56.25 (4.86) 0.117‡
Mean glucose (from
CGMS) (mmol/L)
11.56 (4.06) 9.66 (2.01) 0.392‡
Time in range (from
CGMS) (%)
40.89 (22.84) 60.71 (26.79) 0.132†
Triglycerides (mmol/L) 1.93 (0.63) 1.71 (1.15) 0.583‡
Total Cholesterol (mmol/L) 4.13 (0.61) 3.95 (0.63) 0.552†
Anthropometric measures and blood pressure
Height (cm) 168.78 (5.17) 166.19 (12.32) 0.572†
Weight (kg) 96.67 (19.91) 81.67 (20.60) 0.136†
Waist circumference (cm) 112.39 (12.44) 102.50 (9.80) 0.091†
Hip
circumference (cm)
114.67 (17.71) 108.63 (3.29) 0.945‡
BMI (kg/m2) 34.08 (7.86) 27.61 (2.99) 0.167‡
Waist/hip circumference
ratio
0.99 (0.08) 0.94 (0.74) 0.259†
Systolic BP (mm/Hg) 139.11 (16.83) 133.25 (11.00) 0.416†
Diastolic BP (mm/Hg) 84.99 (7.15) 81.25 (4.65) 0.239†
Beck Depression
Inventory
6.11 (4.83) 9.63 (10.13) 0.725‡
State Anxiety Index 33.11 (8.34) 33.86 (10.67) 0.877†
EQ5D5L
- anxiety 1.44 (0.53) 1.63 (0.92) 1.000‡
- mobility 1.33 (0.50) 1.38 (0.74) 1.000‡
- pain discomfort 2.11 (0.93) 1.88 (0.84) 0.591†
- self-care 1.00 (0.00) 1.00 (0.00) NA
- usual activity 1.56 (0.53) 1.50 (0.76) 0.819‡
- VAS 74.00 (16.96) 80.75 (15.66) 0.409†
PAID 23.06 (17.07) 31.88 (30.66) 0.468†
PROMIS29
- pain intensity 2.33 (2.55) 2.00 (2.77) 0.682‡
- anxiety 2.11 (1.69) 3.25 (4.06) 0.935‡
- depression 1.67 (2.24) 2.38 (3.11) 0.904‡
- fatigue 4.00 (4.03) 4.88 (4.49) 0.678†
- pain interference 2.89 (3.59) 2.00 (3.89) 0.499‡
- physical function 1.78 (1.92) 1.38 (1.77) 0.636‡
- sleep 7.00 (1.12) 7.00 (1.15) 1.000†
- social 11.67 (5.17) 11.88 (3.64) 0.867‡October 2020 | Volume 11 | Article 5†T2 test; ‡Mann-Whitney U test.
HbA1c, glycated haemoglobin; NGSP, National Glycohemoglobin Standardization
Program; IFCC, International Federation of Clinical Chemistry.
EQ5DL, EuroQol-5D; PROMIS-29, Patient-Reported Outcomes Information System
questionnaire; PAID, Problem Areas in Diabetes scale; BMI, Body Mass Index; BP,
blood pressure; VAS, Visual Analogue Scale.70777
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Positive Experience. Participants generally spoke positively about
the program with many mentioning that they felt that it was “a
very good project” (ID 6) and that the pSMAs were enjoyable to
attend (excerpt 1.1a, b). Participants were generally satisfied with
the frequency and duration of the pSMAs (excerpts 1.1c), as well
as the time and location of them (excerpt 1.1d). Further, the
longer duration of the pSMAs was also seen to be beneficial when
compared to the shorter timeframe of individual medical visits
(excerpt 1.1e, f). Participants were also prompted to discuss any
negative impacts they may have experienced during the program.
None of the participants reported having any negative or adverse
events occur during the pSMAs, besides an adverse reaction to
the glucose sensor mentioned below under data collection
(excerpt 1.1g).
Reasons for Participation. The most commonly mentioned rea-
sons for attending the pSMAs were to receive more information
about the disease and treatment (excerpt 1.2a, b), and partici-
pants’ expectation to share experiences as well as learn from
fellow patients with T2DM (excerpt 1.2c). Other reasons for
attending the pSMAs included encouragement from family
(excerpt 1.2d), and an interest in the mindfulness aspect of the
program (excerpt 1.2e).
Barriers to Consistent Participation. Nearly all of the participants
that were interviewed reported missing one out of the eight
pSMAs in the study. Reasons listed for missing a pSMA included
work commitments (excerpt 1.3a), a pre-booked holiday (excerpt
1.3b), and family reasons.
Theme 2: Perceived Effects of the pSMAs
Acceptance. Denial of the importance of diabetes, or even the
diagnosis itself, was mentioned by participants with ID1
describing that they had “tolerated being a diabetic and not
accepted it” (excerpt 2.1a). Some participants indicated that the
stigma surrounding T2DM created feelings of “guilt” (ID 5)
which inhibited their willingness to accept having the disease
(excerpt 2.1b, c). However, these participants felt that attending
the pSMAs helped to reduce the stigma and guilt associated withFrontiers in Endocrinology | www.frontiersin.org 8having T2DM, particularly due to the education they received
surrounding its hereditary component. This, in turn, led to a
sense of acceptance for those who had previously struggled to
come to terms with having T2DM (excerpt 2.1c, d).
Empowerment. All of the participants reported an increase in
diabetes knowledge and awareness since attending the pSMAs.
Some participants felt that they were now better equipped to
manage their diabetes and improve their health (excerpt 2.2a, b).
Further, many participants noted feeling a sense of empower-
ment from the education they received during the pSMAs, with
ID1 saying that the sessions were “all about empowering you”
(excerpt 2.2c, d). Several participants utilized the education they
received during the pSMAs, and applied it in their everyday lives
as listed below under lifestyle modifications. Even those that had
yet to make any lifestyle modifications felt that they were now
more inclined to try and make changes to improve their health
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Ee et al. Shared Medical Appointments and DiabetesLifestyle Modification. Participants reported applying the edu-
cation they received on diabetes, diet, and health during the
pSMAs to their lifestyles. Many of the participants reported an
improved awareness of their diets and the food that they were
consuming (2.3a). This was indicated via changes made to their
diet including reducing consumption of refined carbohydrates
such as rice, bread and pasta (excerpt 2.3b), eating smaller por-
tion sizes (excerpt 2.3c), and making a conscious effort to swap
junk food for healthier options (excerpt 2.3d). Other lifestyle
modifications included making an increased commitment to
looking after health via regular exercise and the practice of
mindfulness made by one participant (excerpt 2.3e). Another
participant mentioned focusing on reducing stress from their life
after learning of the impact it can have on health in one of the
pSMAs (excerpt 2.3f). Several of the participants had not yet
made any lifestyle modifications associated with their partici-
pation in the pSMAs (excerpt 2.3g). Reasons for this included
issues in their personal life (excerpt 2.3h)and difficulty in gaining
motivation to make healthy lifestyle changes (excerpt 2.3i). One
participant also noted that it was more difficult for them to
reduce their carbohydrate intake due to rice being the staple food
in their Asian culture (excerpt 2.3j).
Reported Health Benefits Associated With SMA Participation.
Several participants reported noticing benefits to their health
since participating in the pSMAs. Two of the participants
reported experiencing weight loss (excerpt 2.4a), crediting the
education they received surrounding diet and food choices and
consequent lifestyle changes, as the reasons for this weight loss.Frontiers in Endocrinology | www.frontiersin.org 9One participant noted a decrease in their HbA1c levels at the end
of the pSMAs (excerpt 2.4b), whilst another reported experi-
encing an increase in energy levels as a result of their partici-
pation in the pSMAs (excerpt 2.4c). An increase in joint and
muscle flexibility was also mentioned as a health benefit expe-
rienced by one participant (excerpt 2.4d). A few of the partici-
pants stated that they were yet to experience any health benefits
associated with their participation in the pSMAs (excerpt 2.4e).
These participants were typically the ones that had not yet made
any lifestyle modifications, as mentioned above.
Mindfulness was Helpful for Some. pSMA participants enjoyed
practicing mindfulness and found it beneficial for various rea-
sons. Several participants found that practicing mindfulness
helped to improve the decision-making process behind one’s
dietary choices, which in turn, helped reduce mindless snacking
and the consumption of “junk” food (excerpt 2.5a, b). Others
found that practicing mindfulness improved sleep and enhanced
relaxation and reduced stress (excerpt 2.5c–e). In regard to the
practice of mindfulness at home, approximately half of the
participants reported doing so whilst the other half stated that
they had not yet done so (excerpt 2.5f, g). There were also a few
participants that believed that mindfulness did not have any
impact on their health or wellbeing, specifically stating that
“mindfulness didn’t work” (excerpt 2.5h).
pSMAs Improved Psychosocial Wellbeing. Participating in pSMAs
appeared to positively impact on the mood of many of the partic-
ipants (excerpt 2.6a). Many of the participant responses indicatedFIGURE 2 | Themes and subthemes from qualitative evaluation. pSMAs, programmed Shared Medical Appointments.October 2020 | Volume 11 | Article 570777
Ee et al. Shared Medical Appointments and Diabetesthat they enjoyed attending the fortnightly pSMAs. Some of the
participants also mentioned the mindfulness sessions included in
the pSMAs as a contributing factor to their enhanced mood and
decreased stress levels.
Theme 3: Support and Materials
pSMAs Provided Support and Advice. Content provided during
the education sessions was found to be useful, beneficial, and easy to
understand (excerpt 3.1a). Participants generally found that the
information handouts they received throughout the pSMAs were
useful and straightforward, and a few also mentioned using the
notebook/diary provided to take notes during the session (excerpt
3.1b, c). Participant responses also indicated that they were pleased
with the support and advice provided throughout the pSMAs, with
many stating that they found the facilitators to be helpful and
understanding (excerpt 3.1d). Further, importance was placed on
the ability of the facilitators to create a comfortable environment
and encourage the group to ask questions and share their experi-
ences without feeling insignificant (excerpt 3.1e, f). One participant
described being initially shy to talk in a group setting but once the
pSMAs began they felt comfortable to engage and to ask questions
(excerpt 3.1g). Overall, none of the participants reported any issues
with the level of support and advice they were provided with
throughout the pSMAs.
Group Setting Was Beneficial. The group setting was seen as
beneficial by all participants, particularly because they reported
finding it useful to hear about others experiences with diabetes as
well as to share their own (excerpt 3.2a–c). Further, participants
found it easy to learn from others in this group environment,
mainly in regard to the management of diabetes (excerpt 3.2d, e).
Participants also noted feeling that their different views were
valued (excerpt 3.2f), and stated that they enjoyed bonding with
other people in the “same boat” (ID 1) as them (excerpt 3.2g).
Some participants mentioned an initial concern regarding how
comfortable and willing everyone would be to share their expe-
riences in front of strangers, but one participant found that it “very
quickly became comfortable” (excerpt 3.2h, ID 5). It was also
agreed by many of the participants that it was more favorable to
attend the pSMAs with strangers as opposed to people you know,
such as relatives and friends (excerpt 3.2i). One participant felt
that being with strangers results in a “lack of inhibition and
embarrassment” (ID 2), making it easier to share experiences and
ask questions.
Data Collection Was Acceptable. The participants generally felt
that the data collection process was easy and ran smoothly
(excerpt 3.3a). Participants felt that it was useful to find out their
measurements, including weight and blood sugar levels, and it
was considered a good progress checkpoint by some participants
(excerpt 3.3b, c). There were no major issues with the data col-
lection process; however, one participant had an adverse reaction
to the glucose sensor resulting in blisters and itchiness (excerpt
3.3d). Another participant mentioned receiving incorrect
instructions in regard to the use of the accelerometer. One par-
ticipant also felt that there were “too many questions” (ID 6)
included in the data collection process (excerpt 3.3e).Frontiers in Endocrinology | www.frontiersin.org 10Theme 4: Future Directions
Recruitment Ideas. Promotion of pSMAs via GPs, endocrinol-
ogists, and the National Diabetes Services Scheme (NDSS), as
well as via word of mouth, were all considered to be important
for future SMA recruitment (excerpt 4.1a, b). Further, many of
the participants stated that they would recommend pSMAs to
other T2DM patients (excerpt 4.1c). The challenges to recruit-
ing others to attend SMAs discussed by participants included
potential feelings of shyness inhibiting one’s willingness to share
their experiences in a group setting (excerpt 4.1d) as well as a
lack of time and willingness to commit (excerpt 4.1e).
Ideas for Improvement. Participants were prompted to discuss
aspects of the pSMAs that could be improved to enhance their
effectiveness. Two participants mentioned that they would like
the information delivered during the pSMAs to be provided
digitally via a PDF rather than in hard copy, with one suggesting
the creation of an app that contains this information (excerpt
4.2a, b). With regards to long-term use of pSMAs, participant
responses indicated that they were satisfied with attending over
the 8-week period but would not want to attend for longer
periods of time. However, some of the participants mentioned
continued contact and updates would be useful (excerpt 4.2c).
Secondary Outcomes
Anthropometric Measures
There were no statistically significant differences between groups
at post intervention for weight, waist circumference, hip
circumference, BMI, WHR, or blood pressure (see Table 5).
Glycemic Control and Lipids
There was a trend to improvement in glycemic control (glycated
hemoglobin, continuous glucose levels, and time in range) in the
pSMA group and a deterioration in the usual care group;
however, these differences were not statistically significant.
There was a statistically significant difference between groups
for change in total cholesterol levels, which decreased by 6.5% in
the pSMA group and increased by 5% in the usual care group
(see Table 6).
Psychological Outcomes and Quality of Life
Table 7 presents the findings for psychological outcomes and
quality of life. Psychological outcomes improved in the pSMA
group compared to little change in the usual care group;
however, these changes were not statistically significant. This
included a 36.3% reduction in the Beck Depression Inventory
and 41.5% improvement in the PAID score in the pSMA group.
Fatigue, pain, and physical function improved in the PROMIS
29 domains in the pSMA group but only the change in pain
intensity was statistically significant; however, the mean score for
this suggested low levels of pain intensity at baseline.
Diet and Physical Activity Changes
Table 8 describes the findings for diet and physical activity
changes. There was a significant difference between groups atOctober 2020 | Volume 11 | Article 570777
Ee et al. Shared Medical Appointments and Diabetesbaseline for weekly takeaway intake (p = 0.0451) with the
intervention group consuming a greater number of takeaway
meals than the control group. There was no difference between
groups at post intervention for physical activity levels and
dietary habits.
We were only able to calculate mean minutes per day and
days per week of meditation as many of the logs were incomplete
or reported only according to a brief estimate of time spent
meditating. Minutes per day, days per week of meditation, and
minutes per week of meditation were not normally distributed in
the usual care group due to an outlier who practiced meditation
for an hour a day 7 days a week, and so a non-parametric test was
used. There was no difference between groups for minutes per
day (p = 0.360), days per week (p = 0.479), or minutes per week
(p = 0.626) spent meditating over the intervention period. When
we removed the outlier from the usual care group, there was still
no difference between groups for minutes per day (p = 0.629),
days per week (p = 0.289), or minutes per week (p = 1.00). Table
9 provides details of mean time spent meditating in both groups,
with one outlier removed from the usual care group.Frontiers in Endocrinology | www.frontiersin.org 11Harms
Eighteen adverse events (AE) were reported. Of these, five were
determined to be definitely caused by participation in the trial
(but not due to the intervention itself), and 13 were deemed to
not be related to the intervention. There were three reports of
mild pain around the CGM sensor, which were short-lived and
completed resolved within 10 min. There was one report of itch
and redness around the sensor, which was mild and partially
resolved at the time of follow-up. There was one report of a mild
bruise around the phlebotomy site. The other AEs (which were
deemed not related to the intervention) were back pain, blurred
vision, cough, headache, high glucose level due to a urinary tract
infection, elective surgery for an abdominal hernia, a toe injury
(which did not occur while attending to trial activities), loose
teeth, migraine, tightness of the chest, a tooth extraction, an upper
respiratory tract infection, and visual disturbance. Ten AEs
occurred in the pSMA group (including two definitely related
AEs) and eight in the usual care group (including three definitely
related AEs). One serious AE was reported (elective surgery as





Usual care group mean
baseline (SD)




Weight (kg) 96.67 (19.91) 95. 78 (19.84) 76.63 (14.96) 75.75 (14.98) 0.993†
Waist circumference
(cm)
112.39 (12.44) 111.86 (15.41) 102.50 (9.80) 103.75 (8.24) 0.132‡
Hip
circumference (cm)
114.67 (17.71) 114.20 (17.49) 108.63 (3.29) 107.38 (3.70) 0.510†
BMI (kg/m2) 34.08 (7.86) 33.78 (8.02) 27.61 (2.99) 27.23 (2.83) 0.885†
Waist/hip circumference
ratio
0.99 (0.08) 0.98 (0.66) 0.94 (0.74) 0.97 (0.06) 0.183†
Systolic blood pressure
(mm/Hg)
139.11 (16.83) 137.67 (14.34) 133.25 (11.00) 131.50 (15.79) 0.962†
Diastolic blood pressure
(mm/Hg)
84.99 (7.15) 83.00 (4.50) 81.25 (4.65) 79.88 (8.90) 0.880†October 2020 | Volume 11 | Article 5†T2 test; ‡Mann-Whitney U test.
BMI, Body Mass Index.TABLE 6 | Glycemic control and lipids at baseline and 12 weeks.
pSMA group mean
baseline (SD)
pSMA group mean post
intervention (SD)
Usual care group mean
baseline (SD)




Hb1Ac-NGSP (%) 7.92 (1.09) 7.81 (0.80) 7.30 (0.44) 7.5 (1.03) 0.336†
Hb1Ac-IFCC (mmol/mol) 62.89 (11.90) (11.90)
(11.90)
61.89 (8.67) 56.25 (4.86) 58.50 (11.41) 0.356†
Mean glucose (from
CGMS) (mmol/L)
11.56 (4.06) 10.52 (1.95) 9.66 (2.01) 10.37 (2.49) 0.555‡
Time in range (from
CGMS) (%)
40.89 (22.84) 49.60 (24.23) 60.71 (26.79) 55.14 (30.85) 0.296†
Triglycerides (mmol/L) 1.93 (0.63) 2.13 (1.06) 1.71 (1.15) 2.01 (1.03) 0.583‡
Total Cholesterol (mmol/L) 4.13 (0.61) 3.86 (0.66) 3.95 (0.63) 4.15 (0.73) 0.025‡†T2 test; ‡Mann-Whitney U test; NGSP, National Glycohemoglobin Standardization program; IFCC, International Federation of Clinical Chemistry; CGMS, Continuous Glucose Monitoring
System. Bold figures represent statistically significant differences.70777
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In our mixed-methods study of pSMAs with mindfulness for
people with T2DM within primary care, we demonstrated high
levels of acceptability and feasibility of implementation of both
the intervention and follow-up trial. Notably, the majority of
participants from the pSMA group and half of the participants inTABLE 7 | Psychological outcomes and quality of life at baseline and 12 weeks.
pSMA group mean base-
line (SD)
pSMA group mean post
intervention (SD)
Usual care group mean baseline
(SD)




BDI 6.11 (4.83) 3. 89 (3.30) 9.63 (10.13) 9.88 (11.45) 0.832‡
SAI 33.11 (8.34) 30.11 (8.09) 33.86 (10.67) 36.29 (15.27) 0.281‡
EQ5D5L
- anxiety 1.44 (0.53) 1.44 (0.53) 1.63 (0.92) 1.75 (1.67) 0.817‡
- mobility 1.33 (0.50) 1.22 (0.44) 1.38 (0.74) 1.38 (0.74) 0.939‡
- pain discomfort 2.11 (0.93) 1.67 (0.50) 1.88 (0.84) 2.00 (0.93) 0.187‡
- self-care 1.00 (0.00) 1.00 (0.00) 1.00 (0.00) 1.00 (0.00) NA
- usual activity 1.56 (0.53) 1.22 (0.44) 1.50 (0.76) 1.13 (0.35) 1.000‡
- VAS 74.00 (16.96) 75.44 (14.14) 80.75 (15.66) 75.88 (23.66) 0.646‡
PAID 23.06 (17.07) 13.47 (7.75) 31.88 (30.66) 30.16 (34.03) 0.129†
PROMIS29
- pain intensity 2.33 (2.55) 2.11 (2.37) 2.00 (2.77) 2.38 (2.93) 0.034‡
- anxiety 2.11 (1.69) 1.67 (1.58) 3.25 (4.06) 3.13 (4.39) 0.601‡
- depression 1.67 (2.24) 1.00 (1.58) 2.38 (3.11) 3.75 (4.23) 0.054‡
- fatigue 4.00 (4.03) 3.56 (2.92) 4.88 (4.49) 5.63 (4.81) 0.252†
- pain
interference
2.89 (3.59) 2.67 (3.57) 2.00 (3.89) 2.63 (5.68) 0.388‡
- physical
function
1.78 (1.92) 1.00 (1.12) 1.38 (1.77) 1.88 (2.90) 0.129‡
- sleep 7.00 (1.12) 6.89 (0.78) 7.00 (1.15) 7.75 (0.71) 0.217†
- social 11.67 (5.17) 11.67 (4.72) 11.88 (3.64) 11.75 (4.56) 0.938†October 2020 | Volume 11 | Article†T2 test; ‡Mann-Whitney U test; BDI, Beck Depression Inventory; SAI, State Anxiety Index; EQ5D5L, EuroQol 5 D; PROMIS-29, Patient-Reported outcomes Information System
questionnaire; PAID, Problem Areas in Diabetes Scale. Bold figures indicate statistically significant differences.TABLE 8 | Diet and physical activity habits at baseline and 12 weeks.
pSMA group mean
baseline (SD)
pSMA group mean post
intervention (SD)
Usual care group mean
baseline (SD)




Sedentary behavior per day (min/h
per day of wear time)
859.57/14.3 (134.26/
8.59)
868.60/14.47 (131.21/2.19) 778.48/12.97 (234.25/
3.90)
739.13/12.32 (208.08/3.47) 0.203†
Light PA (min/h per day of wear
time)
168.36/2.806 (51.74) 153.79/2.56 (44.48) 193.37/3.22 (71.85) 197.95/3.30 (63.04) 0.521†
Moderate PA (min per day of wear
time)
34.26 (19.11) 37.37 (26.69) 39.13 (16.54) 39.01 (21.87) 0.308†
Vigorous PA (min per day of wear
time)
0.48 (0.71) 0.40 (0.76) 0.77 (0.86) 0.79 (1.31) 0.876‡
Average MVPA Per Day (min) 34.74 (19.50) 37.77 (27.10) 39.89 (16.65) 39.81 (21.65) 0.365†
Calendar days with wear time 6.71 (0.76) 6.86 (1.07) 6.40 (0.55) 6.00 (0.71) 0.235‡
Total wear Time 7,205.60 (1,457.93) 7363.44 (1785.76) 6,608.25 (1,716.10) 6,411.43 (1,720.19) 0.180†
Daily step count 6,165.66 (2,579.86) 6,476.41 (3,419.28) 8,498.48 (2,329.73) 7,201.38 (1,862.91) 0.699†
% sedentary* 80.60 (5.39) 81.23 (4.02) 74.55 (12.31) 74.07 (10.42) 0.670†
% light PA 16.42 (4.45) 15.30 (3.21) 20.81 (11.20) 21.68 (10.05) 0.419†
% moderate PA 2.97 (1.54) 3.42 (2.41) 4.54 (1.25) 4.13 (1.23) 0.457†
% vigorous PA 0.02 (0.02) 0.41 (0.07) 0.09 (0.10) 0.11 (0.18) 0.935‡
% MVPA 2.99 (1.55) 3.46 (2.44) 4.64 (1.26) 4.24 (1.17) 0.463†
Daily serves of vegetables 2.06 (1.57) 1.75 (1.14) 1.52 (1.04) 1.48 (0.51) 0.799‡
Daily serves of fruit 1.06 (0.39) 1.13 (0.47) 1.37 (0.85) 1.52 (0.62) 0.974†
Weekly serves of takeaways 5.78 (4.74) 4.78 (3.03) 1.89 (2.52) 1.625 (1.30) 1.00‡5
T2 test; ‡Wilcoxon rank-sum (Mann-Whitney); *percentages are reported as percentage of wear time.
Calendar days with wear time at Baseline: 0.222‡.
Calendar days with wear time at Post-intervention: 0.151†.TABLE 9 | Time spent meditating throughout intervention period.
pSMA group (n = 9) Usual care group (n = 7)
Mean minutes per day (SD) 2.14 (2.50) 10.24 (20.33)
Mean days per week (SD) 3.67 (3.54) 1.07 (1.43)
Mean minutes per week
(SD)
14.11 (17.12) 13.10 (20.77)70777
Ee et al. Shared Medical Appointments and Diabetesthe control group reported that there was nothing that they did
not enjoy about taking part in the study. Qualitative evaluation
demonstrated that pSMA participants found the program to be
positive overall, with multiple benefits such as increased
acceptance of their diagnosis, feeling empowered, making
changes with their lifestyle, and enjoying the opportunity to
meet people who were in the “same boat” as them. Our findings
are consistent with previous studies on SMAs for people with
T2DM with patient satisfaction generally being high, diet and
physical activity habits improving, and patients being able to
achieve or almost achieve their self-prescribed goals (10).
SMAs have been promoted as an effective way for clinicians to
deliver care to multiple patients with the same clinical problem,
therefore, increasing provider satisfaction (35–38). The impact
on people with T2DM is multifactorial. The most important
features of the SMAs, according to our participants, were the
ability to share experiences in a group setting, an expanded
knowledge of diabetes, a sense of not being alone, and the style
and approach of the facilitator and GP.
The provision of additional support and advice was an
important component of our pSMAs, according to participants.
The design of SMAs allows for each participant to listen and gain
from questions and answers during others’ medical consultations.
This may have led to the positive changes in lifestyle habits that were
described by some participants. This is supported by the objective
increase in minutes and percentage of wear time spent in moderate
to vigorous physical activity (MVPA) noted in the pSMA group,
whereas there was no change in the control group. This difference
equates to an additional 3 min of MVPA per day or 21 additional
min per week (an increase of 8.6%). Similarly, other studies have
reported improvements in patient engagement after attending
SMAs, such as being able to set and achieve measurable goals and
improvement in knowledge, self-efficacy and self-management (39).
However, no difference between groups was observed for diet
changes in our study, although we did find a statistically
significant difference between groups for total cholesterol.
The group setting was seen as beneficial for several reasons.
Participants described the benefits of being able to learn from
each others’ experiences. The process of sharing one’s
experiences and tips on management of a chronic disease may
increase self-efficacy. It has been described that peer support for
people with T2DM improves clinical and psychological
outcomes particularly in minority populations, and may be
associated with improvements in lifestyle habits, self-care, and
self-efficacy (40–42).
Participants in the pSMA group described the positive impact
of the program on their mental health. This included the ability
to finally accept their diagnosis, the feeling of not being alone in
their experience of T2DM, and being able to finally overcome
guilt and stigma. This was reflected in the improvement in
depressive symptoms and diabetes-related distress in the
pSMA group, although the average score for depression was in
the normal range and it is not clear if these differences are
clinically relevant.
The process of overcoming guilt and stigma not only
benefited mental health in our study; it was described byFrontiers in Endocrinology | www.frontiersin.org 13participants as empowering. Patient empowerment is defined
as “a process through which people gain control over decisions and
actions affecting health” and has been shown to improve self-
management skills in people with T2DM, and have positive
impacts on clinical, lifestyle and psychosocial outcomes,
including diabetes complications (43). Empowerment requires
not only the acquisition of skills and knowledge, but also a
psychologically safe environment that facilitates self-reflection
and self-awareness. People with T2DM commonly experience
feelings of guilt and shame and experience stigma, which may
become barriers toward the management of T2DM such as with
initiating insulin or making lifestyle changes (44–46). These
feelings, as well as fear of being judged by medical doctors,
may act as a barrier to effective communication within a
consultation (47). It was clear that participants felt a strong
rapport with, and benefited from, the therapeutic relationship
with the chosen facilitator and GP. The qualities of being
knowledgeable, friendly and supportive were perceived highly,
and led to participants feeling confident in asking questions and
feeling cared for. Likewise, other studies have highlighted the
importance of establishing trusting and nonjudgmental
relationships within the patient-clinician dyad for people with
T2DM in order to facilitate self-efficacy and improved clinical
outcomes (48).
The combination of provision of knowledge in the
educational component of the pSMAs, the ability to share
knowledge with peers, and the therapeutic alliance with health
providers in a safe environment may have facilitated the trends
toward improvement in some clinical outcomes in the pSMA
group. Although the differences in glycemic control were not
statistically significant between groups, we report HbA1c
improvement of 0.11% in the pSMA group and worsening by
0.2% in the control group. Similarly, mean glucose from CGMS
decreased and time in range increased in the SMA group whereas
the opposite was observed in the control group. This is consistent
with findings from other studies reporting lower HbA1c (10),
however, remains to be confirmed in a fully-powered RCT.
However, there was little change in anthropometric
measurements or blood pressure.
There was a mixed response to the mindfulness component
with some participants providing positive feedback on the guided
mindfulness sessions while others reporting they did not find the
sessions useful. Although systematic reviews on mindfulness
meditation in the general population report improvements in
eating behaviors and physical activity (11–16), the evidence in
T2DM is mixed. Trials that used Mindfulness-Based Stress
Reduction, an intensive 8-week program pioneered by Jon
Kabat-Zinn, have reported improvements in glycemic control
(49) and psychological outcomes (49, 50) with an improvement
in microalbuminuria at one year which was not sustained at two
and three year follow-up (51). Other mindfulness-based
interventions, such as mindful self-compassion, mindfulness-
based cognitive therapy, and Acceptance and Commitment
Therapy, described reductions in depression (52, 53) diabetes-
related distress (52), glycemic control (52, 54), and better
diabetes self-care (54). However, a program of mindful eatingOctober 2020 | Volume 11 | Article 570777
Ee et al. Shared Medical Appointments and Diabeteswas similar to diabetes self-management education for
improvements in depression, nutrition and eating-related self-
efficacy, and cognitive control (55). It is not clear if mindfulness
contributed to improvements in psychological outcomes, lifestyle
habits and glycemic control in our study, although some
participants did describe mindfulness helping them with
making healthier food choices (for example, reducing mindless
snacking) and reducing stress. Reductions in catecholamines
have been described after the practice of mindfulness (51). A
clinical trial comparing SMAs with mindfulness to SMAs alone is
required to evaluate the impact of mindfulness on T2DM
outcomes. Additionally, participants reported needing some
assistance or guidance with home practice, and a more
structured approach to home mindfulness practice may be
required. Last, a limitation of this study design is the lack of an
active control comparator. In order for a follow-up trial to be
methodologically rigorous and add to the body of evidence on
mindfulness, an active control should be utilized (56–58).
Recruitment in this study was highly feasible with 18
participants enrolled within two months. Unfortunately, we
did not collect information on how participants found out
about our study; however, we note that the majority of
enquiries were made after a Diabetes NSW newsletter was
emailed to members. The conversion rate from enquiry to
enrolment was relatively high at 34.6%. This reflects our broad
inclusion criteria. Our retention rate was excellent with only one
participant withdrawing (from the control group). These
findings demonstrate the feasibility of a follow-up fully-
powered RCT within primary care. Additionally, our mixed
methods evaluation of the acceptability of trial procedures
demonstrates that participants were mostly satisfied with trial
procedures. The only issues raised were relatively minor such as
technical problems with the accelerometer or CGMS monitor.
Modifications for a follow-up trial, based on the feedback
from our participants, should include support materials being
delivered electronically, more support and guidance with home
mindfulness practice (for example, direction and reminders to
practice at a particular time of day such as before bed), and use of
Australian CGMS sensors which would allow for real-time
monitoring using a mobile app, reduction in the number of
PROMs to be collected, and presenting information about diet
early on in the program. Additionally, a waitlist control design
would be ideal to maintain engagement within the control group.
To evaluate the effect of SMAs + mindfulness vs. SMAs alone or
waitlist control, a three-armed trial is warranted. Further, the
personal qualities of the GP and facilitator are of great
importance; these health professionals should be non-
judgmental, approachable, supportive, and create trust within
the therapeutic relationship.
Strengths of this study include its mixed-method design
which allowed us to explore, in a profound way, the
experiences of the participants in the pSMA group and how
the pSMAs impacted on their health and wellbeing as well as
their views on the reasons why pSMAs were helpful. We added a
novel component, mindfulness, in order to explore the
relationship between this technique and the ability to makeFrontiers in Endocrinology | www.frontiersin.org 14decisions about healthy lifestyle habits and the impact on
psychological health. We utilized objective and reliable
measures of physical activity, collected outcomes on mental
health and diabetes-related distress, and used continuous
glucose monitoring as an additional measure of glycemic
control. Limitations are the small sample size, including the
sample size for the qualitative evaluation, and the relatively short
duration of treatment of 12 weeks. Due to the pSMAs being
conducted in English, we could not enrol people who could not
understand or converse in English, therefore our findings are
unable to be generalized to non-English speaking populations.
Despite this, there was evidence of cultural diversity within our
sample, with about a third of participants in both groups being of
Asian origin, and a quarter to a third being of Oceanic peoples’
origin. Moreover, scaling up this intervention means that
the same GP and facilitator may not be able to provide the
intervention to all participants, and it is unknown what the
impact of different personalities would be on the overall
experience of pSMAs. This has implications on training and
monitoring of the fidelity of the intervention in a future trial.
Additionally, we did not collect data on provider satisfaction, nor
on whether control group participants used any additional
services such as the GetHealthy NSW coaching service that
was suggested to them, or the meditation app. Future
modifications may also include anthropometric measurements
using bioimpedance to evaluate changes in fat free mass as well as
total body weight, which has a greater impact on clinical
outcomes, and incorporating health economic evaluation.CONCLUSION
Our program of pSMAs with mindfulness within primary care
was acceptable and generally enjoyable for participants and led to
improvements in diabetes knowledge, lipids, and psychological
health. It is likely that these benefits were mediated by multiple
factors such as the group setting (with peer support and
realization that one is not alone in their experience of T2DM),
improved knowledge and support facilitating improved lifestyle
behaviors, and a strong therapeutic relationship with the
facilitator and GP resulting in improved engagement and self-
efficacy. Therefore, pSMAs may represent a cost-effective and
time-efficient enhancement to T2DM management within
primary care. Mindfulness may also have played a role in
helping improve dietary choices and reducing stress for some
participants. Our mixed methods study demonstrates feasibility
of both the intervention and a follow-up fully-powered RCT to
confirm or refute these benefits.DATA AVAILABILITY STATEMENT
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